Idogen's CEO Anders Karlsson leaves for a new assignment and Christina Herder is appointed acting CEO
Idogen AB (publ) announces today that Anders Karlsson has decided to leave the company to move on to a CEO role in another Swedish biotechnology company. He will remain in his current position until 1 September 2022; the board is now starting a process to recruit a successor. Christina Herder, who has been a board member of the company for more than five years, has been appointed acting CEO while the recruitment of a new CEO is underway. She will retain her role on the board during this time.
"It has been a privilege to lead Idogen for the past three years and I am convinced that the company's competent board and employees will continue to deliver significant progress for the benefit of large patient groups as well as the shareholders," says Anders Karlsson, resigning CEO of Idogen.
“I am looking forward to being operationally involved in the advancement of the IDO 8 program in these exciting times, as we soon will be starting our Phase I/IIa study in the Nordic region,” says Christina Herder, incoming CEO of Idogen.
Idogen develops tolerogenic cell therapies with the potential to restore the tolerance of the immune system in order to counteract its attacks against biological drugs, transplanted organs or the body's own tissue. The company's most advanced project IDO 8 aims to treat hemophilia patients who have developed an incorrect immune response to their drug treatment. Idogen has received approval from the Swedish and Norwegian pharmaceutical authorities to start a first clinical phase I/IIa study with IDO 8 in patients with hemophilia.
For further information, please contact:
Agneta Edberg, chairman of the board, Idogen AB
Phone: +46 70 555 75 18
Certified Advisor:
The companies Certified Advisor is Vator Securities AB. Contact information : Vator Securities AB, Kungsgatan 34, SE-111 35 Stockholm,
Email: ca@vatorsec.se.
Tel: +46 (0)8-580 065 99
The information is information that Idogen AB is obliged to make public pursuant to the EU Market Abuse Regulation, through the agency of the contact persons set out above, on 10 August 2022 at 17:30 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own
cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com
